491 related articles for article (PubMed ID: 37445976)
1. Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.
Bertoli E; De Carlo E; Basile D; Zara D; Stanzione B; Schiappacassi M; Del Conte A; Spina M; Bearz A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445976
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
3. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
4. Future Perspectives in Detecting
Ferreira D; Miranda J; Martins-Lopes P; Adega F; Chaves R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916986
[TBL] [Abstract][Full Text] [Related]
5. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.
Zhang YC; Zhou Q; Wu YL
J Hematol Oncol; 2017 Oct; 10(1):167. PubMed ID: 29061113
[TBL] [Abstract][Full Text] [Related]
6. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
8. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.
Ren J; Liu R
Methods Mol Biol; 2023; 2695():145-163. PubMed ID: 37450117
[TBL] [Abstract][Full Text] [Related]
9. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies.
Chang L; Li J; Zhang R
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188729. PubMed ID: 35436521
[TBL] [Abstract][Full Text] [Related]
13. Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.
Palmieri M; Frullanti E
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36649045
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
15. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Rolfo C; Mack P; Scagliotti GV; Aggarwal C; Arcila ME; Barlesi F; Bivona T; Diehn M; Dive C; Dziadziuszko R; Leighl N; Malapelle U; Mok T; Peled N; Raez LE; Sequist L; Sholl L; Swanton C; Abbosh C; Tan D; Wakelee H; Wistuba I; Bunn R; Freeman-Daily J; Wynes M; Belani C; Mitsudomi T; Gandara D
J Thorac Oncol; 2021 Oct; 16(10):1647-1662. PubMed ID: 34246791
[TBL] [Abstract][Full Text] [Related]
17. Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V; La Mantia M; Peri M; Iacono F; Barraco N; Perez A; Viscardi G; Cutaia S; Russo TDB; Anwar Z; Incorvaia L; Fulfaro F; Vieni S; Pantuso G; Graceffa G; Russo A; Galvano A; Bazan V
Crit Rev Oncol Hematol; 2023 Feb; 182():103899. PubMed ID: 36596401
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer.
Chen K; Kang G; Zhao H; Zhang K; Zhang J; Yang F; Wang J
Expert Rev Mol Diagn; 2019 May; 19(5):419-427. PubMed ID: 30905203
[TBL] [Abstract][Full Text] [Related]
19. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.
Malapelle U; Pisapia P; Addeo A; Arrieta O; Bellosillo B; Cardona AF; Cristofanilli M; De Miguel-Perez D; Denninghoff V; Durán I; Jantus-Lewintre E; Nuzzo PV; O'Byrne K; Pauwels P; Pickering EM; Raez LE; Russo A; Serrano MJ; Gandara DR; Troncone G; Rolfo C
Expert Rev Mol Diagn; 2021 Nov; 21(11):1165-1178. PubMed ID: 34570988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
